Search PubMed⌕ Search

Biomedical subjects

B Reichart

Publications and source records attributed to B Reichart.

At least 199 records · Page 11Linked to original sources

Haemodynamic and echocardiographic characteristics of a stentless allograft mitral prosthesis: an in vitro study.

Poor long-term durability and impaired haemodynamic performance are known disadvantages of bioprosthetic heart valves when compared to valve replacement using aortic allografts. A new stentless allograft mitral implant was developed and tested in vitro in a left ventricular model and pulsatile flow system to evaluate hydrodynamic function. Mitral valves were excised from sheep hearts and the mitral annulus reinforced by a strip of ovine pericardium. A patch of expanded polytetrafluoroethylene (ePTFE) was placed above the tips of the remaining papillary muscles. For in vitro evaluation of a total of five valves were investigated in a pulse duplicator. Transvalvular pressure gradients (delta P) were measured over a flow range corresponding to a cardiac output of 5l/min, at a heart rate of 70 beats/min, with a systole accounting for approximately 35% of the cardiac cycle. The systolic ejection period and diastolic filling period in this model were 350 and 510 ms, respectively, and aortic pressure was 120/80 mmHg. The effective orifice area was calculated from measurements of mean pressure drop and root mean square flow. Additionally, valve performance was evaluated by Doppler echocardiography. Results of in vitro studies of a 25 mm stentless allograft mitral implant, which is similar to the valves implanted in a chronic weaning sheep model, revealed a mean(s.d.) delta P of 2.0(1.6) mmHg (range 1.0-4.9 mmHg). The mean calculated effective orifice area was 3.38(0.52) cm(2) (range 2.5-3.8 cm(2)). Doppler echocardiography showed excellent performance of the mitral valve components and valve competence could be achieved. During the in vitro studies no failure caused by tissue rupture was detected. The results of the in vitro studies revealed data for delta P and effective orifice area superior to data obtained for standard 25 mm porcine bioprostheses.

Animals↗

Total replacement of the mitral apparatus with a stentless, chordally supported mitral valve allograft: an experimental study.

Mitral valves, including the papillary muscles, were harvested from freshly slaughtered sheep and implanted in 10 recipient growing sheep. A strip of ovine pericardium was used to reinforce the anulus and a patch of expanded polytetrafluoroethylene was used to cover the donor papillary muscle. In four valves the natural chordae tendineae at the anterior cusp were supported by two pairs of 5-0 expanded polytetrafluoroethylene sutures. At the beginning of the experiment two animals died early of valve incompetence. Another animal had to be put to death because of paraplegia after extracorporeal circulation and one died on postoperative day 41 of endocarditis. Six sheep were electively put to death, five after 153 +/- 8 days and one after 43 days. At the time of follow-up, a complete hemodynamic study including echocardiography and stress testing was performed. Heart rate at rest was 91 +/- 14 beats/min, left ventricular systolic pressure 96 +/- 20 mm Hg, left ventricular end-diastolic pressure 11 +/- 5 mm Hg, cardiac output 2.04 +/- 0.40 L/min, and the mean transvalvular pressure gradient was 4.9 +/- 2.8 mm Hg as measured by cardiac catheterization. Echocardiography showed excellent movement of all valve components. However, minor regurgitation was evident in one case. Gross morphologic characteristics showed good healing at the anulus and host papillary muscle; in one case there was a rupture of one small first-order chorda. On radiography no signs of calcification were evident. Light microscopy revealed minor to moderate collagen degeneration in all valve components. However, on electron microscopy the presence of numerous fibroblasts within the long-term implants indicated the biosynthesis of new collagen. In summary, allograft mitral valve replacement seems to be a promising procedure if the chordae tendineae are reinforced by expanding polytetrafluoroethylene sutures.

Animals↗

An imbalance in T-helper cell subsets alters immune response after cardiac surgery.

Growing evidence indicates that cell-mediated immunity is altered after cardiac surgery with cardiopulmonary bypass (CPB). The objective of this prospective randomized study was to investigate (1) if an imbalance in T-helper cell (TH) subsets, i.e. TH1/TH2, may be responsible for these alterations and (2) if they can be counteracted. Twenty patients formed control group A. Twenty group B patients received indomethacin and thymopentin for immunomodulation. In vitro tests included measurements of TH, interleukin (IL)-2 as a cytokine primarily produced by TH1 cells, and IL-6 as a cytokine primarily produced by TH2. Delayed-type hypersensitivity (DTH) skin response and specific antibody (AB) production were used as in vivo tests for TH1- and TH2-induced immune response, respectively. Postoperatively, group A patients showed a persistent, significant reduction of TH, IL-2 synthesis and DTH skin response as compared to baseline values, while IL-6 synthesis remained unaltered and AB production increased (P < 0.05). In group B patients no change in TH, IL-2 and IL-6 synthesis, or DTH skin response was observed (P < 0.05 vs A). Postoperative AB production increased significantly in group B. These results indicate a significant suppression of TH1-induced cell-mediated immune response following CPB, while TH2-induced response remains normal. A normal TH2 response may be helpful for recovery following cardiac surgery by cleaning the body of the byproducts of CPB. A suppression of TH1 response may gain clinical significance whenever a postoperative infection requires this response, but can be effectively counteracted by immunomodulatory intervention with indomethacin and thymopentin.

Aged↗

Assessment of myocardial reinnervation in cardiac transplants by positron emission tomography: functional significance tested by heart rate variability.

While it is known that scintigraphically measured uptake of [C-11] hydroxyephedrine (HED) correlates well with the catecholamine uptake and storage in the nerve terminals of the myocardium, the functional significance of this morphologic marker remains unclear. It had been shown that normal, innervated myocardium exhibits pronounced heart rate variability (HRV). In this study, parallel to the scintigraphic determination of regional HED uptake, the functional sympathetic innervation of the left ventricle was measured by spectral analysis of HRV. Prior to PET scanning, changes in the low frequency HRV after tilt were determined as validated marker of sympathetic function in 12 patients with cardiac transplants (mean time after transplantation 4.7 years). Dynamic PET data acquisition allowed the definition of a retention index as regional marker for sympathetic nerve terminals. Intensity as well as regional extent of this marker were then compared to the results of HRV studies. Two groups were defined based on the scintigraphic findings: 8 of 12 patients displayed regionally increased HED retention (11.5 +/- 3.1%/min.) in the anteroseptal region of the left ventricle, while 4 patients showed little HED uptake (4.3 +/- 0.5%/min.). Uptake values tended to increase for longer times after surgery. Average HRV in the first group (7.57 +/- 7.47 ms2/Hz) was significantly higher (p < 0.05) compared to the low HED uptake group (1.17 +/- 1.08 ms2/Hz). HRV was lower than normal values even in the first group. These independent electrophysiological measurements prove the significance of HED retention for the functional characterization of reinnervation in cardiac transplants.

Adult↗

Clinical relevance of heart rate variability changes after heart transplantation.

Heart rate variability (HRV) of the healthy innervated heart is controlled and regulated by the autonomous nervous system and is influenced by respiratory frequency. Physiologically, there are slow and fast variations of heart rate which are of sympathetic or parasympathetic origin respectively. Spectral analysis of heart rate variability permits a selective quantification of these periodic influences of autonomous neural control. In the absence of neural influence on the pacemaker of the donor heart, we do not expect a high periodic heart rate variability (HRV). Due to the almost rigid heart rhythm we only anticipate a slight deviation of the R-R intervals from their mean value. Interventions such as valsalva maneuvers, controlled respiration and tilt table result in a very small but significant change of heart rate variability. These changes are most likely due to local influences at the donor sinus node. Neural influences from reinnervation may also play an important role in patients long after transplantation.

Acute Disease↗

25 years follow-up of patients after replacement of the aortic valve with a Smeloff-Cutter prosthesis.

Thirty years ago the Smeloff-Cutter double-caged ball prosthesis was developed for aortic valve replacement. Between 1967 and 1977 a total of 46 patients admitted to the University Hospital Munich underwent an isolated aortic valve replacement with the Smeloff-Cutter prosthesis. Postoperatively all patients received anticoagulation treatment with phenprocoumon (Marcumar). A retrospective follow-up of 95.6% of patients, representing 842 patient years, was completed. The corresponding actuarial survival rates after 10, 20, and 25 years were 69.1%, 47.4%, and 31.4%. The actuarial freedom rates from either valve-related complications, reoperations, or death were 72.9%, 47.4%, and 20.3%. Thromboembolism occurred in 1.41% per patient year, bleeding in 1.90%. The rates of valvular dysfunction, reoperation, and endocarditis were 1.16%, 1.16%, and 0.2% per patient-year. Today, of the surviving patients 81% are in NYHA Class I or II, 19% in NYHA Class III. No surviving patient deteriorated over the reported time in his or her functional NYHA classification. After 25 years the Smeloff-Cutter valve has proved to be a reliable prosthesis for aortic valve replacement and-together with the Starr-Edwards prosthesis-it has set a standard in longterm durability by which all other valve designs will have to be measured.

Adolescent↗

[The value of ultrafast computerized tomography in detection of the patency of coronary bypasses].

Bypass graft patency with ultrafast computed tomography (= Electron Beam Tomography, EBT) was examined in 72 bypass grafts (47 saphenous veins, 25 internal mammary arteries) in 30 patients and compared with coronary angiography. Angiography was performed a mean of 4.4 +/- 3.5 months (range 1-13) from the EBT examination. Contrast material (120 ml) was continuously administered via a peripheral vein and 40 axial slices (3 mm slice thickness, 110 ms scan time) without overlap sequences were obtained, ECG triggered with the single slice scanner mode. Imaging of internal mammary artery grafts began at the thoracic inlet, for saphenous vein grafts, at the undersurface of the aorta. Sixty of 63 angiographically patent bypass grafts were determined patent by EBT (sensitivity 95%), 8 bypass grafts could not be detected by EBT, and 9 were angiographically occluded (specificity 89%). Twenty-four of 25 internal mammary artery grafts were patent at EBT and coronary angiography, one was occluded. In 27 of the 30 patients (90%), all of the angiographically patent grafts could be confirmed as open with EBT. Obstructions of 10 grafts could not be visualized with EBT. Graft insertion into native coronary vessels could be visualized in axial slices, although morphologic quantification of graft insertion stenosis (75-90%) in two cases was not possible. Three dimensional reconstruction of the 40 axial slices allowed graft anatomy to be delineated. Visualization of bypass insertion into the native coronary vessel was less successful because of opacification of the left and right ventricle. Electron beam computed tomography is a minimally invasive procedure capable of evaluating the patency of saphenous vein and internal mammary artery grafts. The morphologic quantification of graft obstruction and visualization of the insertion of the bypasses into the native coronary vessels is less successful with present technology and imaging modalities.

Aged↗

[Quality assurance in heart surgery. General and personal concepts].

In the era of managed health care quality assurance has become more and more important. In cardiac surgery immense costs have to be justified. Some of the patients might be treated alternatively with drugs or by cardiological interventions. Additionally, the operative risk is still not neglectable in cases with substantial comorbidities and advanced age. Therefore in Germany, a nationwide quality assurance system was established in 1992 covering more than 90% of the cases in more than 90% of the centers. The goals of quality assurance have to address the needs of the patients, insurance companies, and surgeons, and thereby define the primary endpoints for analysis: mortality, quality of life, and therapy costs including reinterventions. A precondition for a sufficient quality assurance system is the isolation of quality relevant data by multivariate analysis and its documentation. Weighing the different factors allows a risk stratification in order to compare the results of various centers with different patient populations. For every center an expected mortality is calculated, and compared with the observed mortality. By taking the average mortality into account a risk adjusted mortality is derived for every center, which is independent from the patient population. An automated continuous follow-up of the patients is essential and allows assessment of 30-day mortality, reinterventions and quality of life. In 1986, the German Society of Cardio-thoracic-surgery initiated the development of a multicentric method of quality assurance (Quadra). In 1992 the insurance companies agreed to cover the costs for the reduced documentation of 205 parameters for every patient undergoing CABG, valve surgery or repair of an aneurysm with the help of cardio-pulmonary bypass; a 30-day follow up is included. Isolation of risk factors has not been performed because the quality of the data was not considered valid due to incomplete documentation and non-rigorous data control. For the first time in 1990, New York State Department of Health published data on risk adjusted mortality in CABG separate for every hospital. Due to a lawsuit brought on by the journal "Newsday" the department was forced to publish the results of every surgeon. Each clinic reports 41 different patient parameters, which are controlled for completeness and accuracy by an independent committee. The efficacy of this system has been proved by a 41% reduction in mortality from 1989 to 1992 mainly due to changes in patient management. Raw mortality rates to different hospitals in CABG were published by the administration of the insurance companies in 1986 leading to misinterpretations by the public. In response, the Society of Thoracic Surgeons initiated a database to calculate risk adjusted data. Today, more than 50% of all US-American centers participate and more than 700,000 patients have been reported. The data is not controlled and the majority of participating hospitals are small community centers. We have developed a methodology of quality assurance which estimates the operative risks of an individual patient by calculating the survival curve of all patients with the same risk profile who have already been operated on in our center. An automated long-term follow-up at one and five years after surgery provides the data for the calculation. The development of an effective quality assurance in the US was forced by media and insurance companies. Presentation of incorrect or misleading data in Germany has already damaged the image of cardiac surgery and surgeons. Therefore, there are no alternatives to public presentation of risk-adjusted mortalities in order to regain trust. Fears of surgeons and hospitals with results below the average are serious and patients with a high mortality risk may be afraid of not being operated on, although the New York System shows that these fears have not become real...

Cardiac Surgical Procedures↗

Determinants of cerebral oxygenation during cardiac surgery.

BACKGROUND: Neuropsychological deficits after cardiac surgery are attributed to the side effects of cardiopulmonary bypass (CPB). To protect the brain from ischemic damage, the influences of temperature, blood pressure, blood gases, acid-base status, and hemodilution on cerebral oxygenation have to be elucidated and quantified. METHODS: Forty-one consecutive patients were investigated during cardiac surgery while on CPB. Operative management included moderate hypothermia of 26 degrees C and the alpha-stat pH management. With near-infrared spectrophotometry, changes in oxygenated hemoglobin (HbO2, representing oxygen delivery) and oxidized cytochrome a,a3 (CtO2, cellular oxygenation) in brain tissue were obtained noninvasively. In addition, venous saturation of the brain was measured via a catheter in the jugular bulb (SBJO2). The influence of operative management parameters on cerebral oxygenation was calculated by univariate and multiple regression analyses. RESULTS: Before and after CPB there was no significant multivariate determinant of cerebral oxygenation. During CPB, HbO2 depended solely on PCO2 (P < .01; r = .89). CtO2 was determined by pH (P < .01), esophageal temperature (P < .01), PCO2 (P < .01), and Hb (P < .01). These parameters explained nearly all changes of the cytochrome measurements during CPB (r = .99). Arterial PCO2 (P < .01) and pH (P < .01) influenced brain venous oxygen saturation (SBJO2; r = .98). CONCLUSIONS: Cerebral oxygenation is autoregulated during cardiac surgery before and after CPB. During CPB, Hb, temperature, pH, and PCO2 determined at least 85% of all changes in cerebral oxygenation. The main causes of impaired cerebral oxygenation are the decrease in Hb with hemodilution, vasoconstriction due to hypocapnia, and the leftward shift of the Hb binding curve in alkalosis and hypothermia.

Adult↗

Immunologic reaction and viability of cryopreserved homografts.

Homograft cell viability after cryopreservation was investigated and cytoimmunologic monitoring was performed during the early postoperative course to research possible immunologic reactions after allograft aortic valve replacement. After cryopreservation, morphologic observations were made, a nonradioactive cell proliferation assay was used, and prostaglandin I2 secretion of the remaining endothelial cells was determined. Cytoimmunologic monitoring was performed daily within the first 3 weeks postoperatively. An increase of the activation index greater than 1 was rated as an immunologic reaction. Maintained metabolic activity of graft endothelial cells after cryopreservation was confirmed by prostaglandin I2 release (9.24 +/- 3.48 ng/cm2 basic release and 20.1 +/- 5.76 ng/cm2 when stimulated with 25 mumol/L Na arachidonic acid). Cell proliferation was indicated after graft incubation with the nonradioactive viability kit (0.27 +/- 0.9 at 450 nm). Cytoimmunologic examinations (n = 861) after homograft implantation showed a more intense activation in patients with ABO-incompatible grafts (activation index 2.1 +/- 1.6, n = 16) than in those with ABO-compatible grafts (activation index 1.3 +/- 0.8, n = 17). In these groups, the duration of activation by cytoimmunologic monitoring was 2.8 +/- 1.5 days and 1.3 +/- 0.6 days, respectively (p < 0.041). No activation was observed in 8 patients after xenograft valve replacement (p < 0.01). Our data indicate that cryopreservation of homograft valves represents a cell- and tissue-protective preservation method. Postoperatively, all homograft valves caused immunologic reactions, which were reversible without immunosuppression treatment.

ABO Blood-Group System↗

Experience with the Novacor left ventricular assist system as a bridge to cardiac transplantation, including the new wearable system.

The three components of the Novacor left ventricular assist system, compact controller, battery, and back-up battery, have been miniaturized in the development of the wearable system. Therefore patients can be fully mobilized receiving mechanical circulatory support while awaiting heart transplantation. Between February 1992 and April 1994 a total of eight patients with decompensated heart failure (6 dilated cardiomyopathy, 1 acute myocarditis, 1 ischemic cardiomyopathy) were treated with the Novacor left ventricular assist systems. In the most recent four cases the wearable system (N100P) was used. Patients' ages ranged from 17 to 49 years. In five patients severe failure of the right side of the heart was present at the time of implantation. Hemodynamic stabilization was achieved in all patients during the 2 to 122 days (mean 30.8 +/- 42.5 days) of support. The following parameters were measured on average before and 24 hours after implantation of the left ventricular assist system: mean arterial pressure 70 +/- 11 versus 87 +/- 13 mm Hg (p < 0.05), cardiac index 1.71 +/- 0.42 versus 3.23 +/- 0.74 L/min/m2 (p < 0.05), pulmonary capillary wedge pressure 27.1 +/- 4.4 versus 9.9 +/- 5.2 mm Hg (p < 0.01), mean pulmonary pressure 41 +/- 9 versus 27 +/- 6 mm Hg (p < 0.05), and right ventricular ejection fraction 16.7% +/- 10.3% versus 22.0% +/- 11.6% (not significant). Patients who received the wearable system were capable of managing their own power supply during the bridging period and were able to walk to the hospital park and shopping area. One patient had a serious pulmonary infection, which was treated successfully, and two patients had a cerebrovascular accident, which resolved in one and resulted in a minor residual deficit in the other. All eight patients received a heart transplant. One patient died early after transplantation and seven patients are alive and well. In summary, the wearable Novacor left ventricular assist system provides major advantages regarding quality of life of patients during mechanical circulatory support. However, there is a remaining risk of thromboembolism despite anticoagulation therapy.

Adolescent↗

Postoperative neuropsychological dysfunction and cerebral oxygenation during cardiac surgery.

In 41 patients undergoing cardiac operations with extracorporeal circulation, oxidized cytochrome a,a3(CtO2), deoxygenated hemoglobin (Hb), and oxygenated hemoglobin (HbO2) were measured in brain tissue by near-infrared spectrophotometry (NIRS) intraoperatively. Monitoring also included electroencephalography (EEG) and jugular-bulb venous saturation (SBJO2). All operations were performed using membrane oxygenators, moderate hypothermia (26-28 degrees C) and pH alpha-stat management. During cardiopulmonary bypass (CPB) CtO2 and HbO2) were reduced, reaching minimal values when rewarming was instituted. At the end of the operation CtO2 and HbO2 had regained initial levels. During CPB, arterial PCO2, pH, and temperature were closely related to CtO2 (r = 1000, r = -0.964 and 0.929 respectively; p < 0.001, p < 0.001, and p < 0.003 respectively). Neuropsychological testing by the Mini-Mental-State Test indicated reversible postoperative neuropsychological deficits in four patients. There patients had a lower CtO2 minimum compared to those without these deficits (-4.5 mumol/L v. -0.7 mumol/L; p = 0.036). These findings support the hypothesis that neuropsychological deficits in patients after cardiac surgery can be caused by intraoperative cerebral hypoxia.

Adult↗